Next Article in Journal
Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance
Next Article in Special Issue
Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities
Previous Article in Journal
Is the Skin Absorption of Hydrocortisone Modified by the Variability in Dosing Topical Products?
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(1), 10; https://doi.org/10.3390/pharmaceutics10010010

Ophthalmic Drug Delivery Systems for Antibiotherapy—A Review

1
Univ Lyon, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS), Laboratoire d’Automatique et de GEnie des Procédés (LAGEP) Unité Mixte de Recherche UMR 5007, 43 boulevard du 11 novembre 1918, F-69100, Villeurbanne, France
2
Horus Pharma, Cap Var, 148 avenue Georges Guynemer, F-06700 Saint Laurent du Var, France
3
Univ Lyon, Université Claude Bernard Lyon 1, Institut des Sciences Pharmaceutiques et Biologiques (ISPB)—Faculté de Pharmacie de Lyon, 8 avenue Rockefeller, F-69008, Lyon, France
4
Unité de Recherche sur les Maladies Infectieuses et Tropicales Émergentes (URMITE), Unité Mixte de Recherche 6236 Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université, Faculté de Médecine et de Pharmacie, F-13005 Marseille, France
*
Author to whom correspondence should be addressed.
Received: 13 November 2017 / Revised: 4 January 2018 / Accepted: 9 January 2018 / Published: 13 January 2018
(This article belongs to the Special Issue Advanced Ocular Drug Delivery)
View Full-Text   |   Download PDF [1405 KB, uploaded 16 January 2018]   |  

Abstract

The last fifty years, ophthalmic drug delivery research has made much progress, challenging scientists about the advantages and limitations of this drug delivery approach. Topical eye drops are the most commonly used formulation in ocular drug delivery. Despite the good tolerance for patients, this topical administration is only focus on the anterior ocular diseases and had a high precorneal loss of drugs due to the tears production and ocular barriers. Antibiotics are popularly used in solution or in ointment for the ophthalmic route. However, their local bioavailability needs to be improved in order to decrease the frequency of administrations and the side effects and to increase their therapeutic efficiency. For this purpose, sustained release forms for ophthalmic delivery of antibiotics were developed. This review briefly describes the ocular administration with the ocular barriers and the currently topical forms. It focuses on experimental results to bypass the limitations of ocular antibiotic delivery with new ocular technology as colloidal and in situ gelling systems or with the improvement of existing forms as implants and contact lenses. Nanotechnology is presently a promising drug delivery way to provide protection of antibiotics and improve pathway through ocular barriers and deliver drugs to specific target sites. View Full-Text
Keywords: antibiotics; ocular drug administration; nanoparticles; drug delivery antibiotics; ocular drug administration; nanoparticles; drug delivery
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Dubald, M.; Bourgeois, S.; Andrieu, V.; Fessi, H. Ophthalmic Drug Delivery Systems for Antibiotherapy—A Review. Pharmaceutics 2018, 10, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top